Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Spiegelman Daniel K
Relationship:   Director
City:  
State:  
   
Insider Summary:
  
   
Companies Owned :   5    
Direct Shares   148,092    

Indirect Shares

   6,673      
Direct Value   $4,955,193    

Indirect Value

   $0      
Total Shares   154,765      
Total Value   $4,955,193      


CV Therapeutics Inc $0 Biomarin Pharmaceutical Inc $4,226,410 Myriad Genetics Inc $728,782 CV Therapeutics Inc $0 Biomarin Pharmaceutical Inc $4,226,410 Myriad Genetics Inc $728,782
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    0   
    0    

     Stock price went up :
    0   
    0    
     Stock price went down :
    0   
    0    
   
     Gain/Loss Ratio :
   0.0   
   0.0   
     Percentage Gain/Loss :
     0.0%
   0.0%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            CV Therapeutics Inc CVTX SVP, CFO 2009-04-09 67,489 2009-04-09 6,673    Premium*  
            Cascadian Therapeutics, Inc CASC Director 2018-03-09 0 2009-12-04 0    Premium*  
            Biomarin Pharmaceutical Inc BMRN EVP, Chief Financial O... 2019-04-30 47,686 2012-05-29 0    Premium*  
            Relypsa Inc RLYP Director 2016-09-01 0 2015-06-04 0    Premium*  
            Myriad Genetics Inc MYGN Director 2024-06-04 32,917 2020-05-27 0    Premium*  
* Premium Members only  

Records found :    182         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 6 of 8
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2016-08-01 4 AS $99.33 $397,320 D/D (4,000) 42,944 0 -
RLYP Relypsa Inc Director   –       •      –    2016-09-01 4 D $32.00 $39,584 D/D (1,237) 2,250 0 -
RLYP Relypsa Inc Director   –       •      –    2016-09-01 4 D $32.00 $72,000 D/D (2,250) 0 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2016-10-31 4 A $68.44 $10,677 D/D 156 43,100 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2016-11-09 4 S $90.61 $1,812,206 D/D (20,000) 23,100 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-01-09 4 AS $90.00 $450,000 D/D (5,000) 18,100 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-02-24 4 A $0.00 $0 D/D 12,247 30,347 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-02-28 4 OE $63.10 $1,893,000 D/D 30,000 60,347 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-02-28 4 AS $94.00 $2,820,000 D/D (30,000) 30,347 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-03-01 4 AS $94.50 $472,500 D/D (5,000) 25,347 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-03-03 4 D $93.95 $214,488 D/D (2,283) 23,064 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-03-06 4 AS $93.32 $214,916 D/D (2,303) 20,761 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-03-15 4 D $92.50 $397,843 D/D (4,301) 16,460 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-03-16 4 AS $91.96 $182,908 D/D (1,989) 14,471 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-03-22 4 A $0.00 $0 D/D 12,200 26,671 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-04-28 4 A $70.30 $10,897 D/D 155 26,826 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-05-15 4 D $91.50 $157,563 D/D (1,722) 25,104 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2017-06-02 4 D $90.72 $163,387 D/D (1,801) 23,303 0 -
CASC Cascadian Therapeutics, I... Director   –       •      –    2017-06-12 4 D $3.34 $1,794 D/D (537) 12,432 0 -
CASC Cascadian Therapeutics, I... Director   –       •      –    2017-06-12 4 OE $0.00 $0 D/D 2,148 12,969 0 -
CASC Cascadian Therapeutics, I... Director   –       •      –    2017-06-24 4 OE $0.00 $0 D/D 9,058 21,490 0 -
CASC Cascadian Therapeutics, I... Director   –       •      –    2017-06-24 4 D $3.78 $8,562 D/D (2,265) 19,225 0 -
CASC Cascadian Therapeutics, I... Director   –       •      –    2017-09-24 4 OE $0.00 $0 D/D 2,375 21,600 0 -
CASC Cascadian Therapeutics, I... Director   –       •      –    2017-09-24 4 D $3.94 $2,340 D/D (594) 21,006 0 -
BMRN Biomarin Pharmaceutical I... EVP, Chief Financial Officer   •       –      –    2018-02-26 4/A A $0.00 $0 D/D 12,615 70,215 0 -
  182  Records found
  1   2   3   4   5   6  7   8      
  Page 6 of 8  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us